Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Orchard Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Orchard Therapeutics' CEO'su Bobby Gaspar, Mar2020 tarihinde atandı, in görev süresi 3.83 yıldır. in toplam yıllık tazminatı $ 1.45M olup, şirket hissesi ve opsiyonları dahil olmak üzere 39.6% maaş ve 60.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.16% ine doğrudan sahiptir ve bu hisseler $ 611.47K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.7 yıl ve 5.6 yıldır.

Anahtar bilgiler

Bobby Gaspar

İcra Kurulu Başkanı

US$1.4m

Toplam tazminat

CEO maaş yüzdesi	39.6%
CEO görev süresi	3.8yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.7yrs
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Aug 04

Orchard Therapeutics: Shadow Of Former Glory

Jan 20

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Aug 16

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Jun 14

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Feb 03

Orchard Therapeutics appoints Braden Parker as chief commercial officer

Jan 29

Orchard Therapeutics' OTL-200 wins FDA's RMAT status

Jan 14

Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022

Jan 12

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Jan 08

Orchard Therapeutics' MLD gene therapy wins European nod

Dec 21

Our View On Orchard Therapeutics

Dec 17

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Dec 11

Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study

Dec 08

Orchard Therapeutics (ORTX) Investor Presentation - Slideshow

Nov 22

CEO Tazminat Analizi

Bobby Gaspar'un ücretlendirmesi Orchard Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2023	n/a	n/a	-US$73m
Jun 30 2023	n/a	n/a	-US$85m
Mar 31 2023	n/a	n/a	-US$124m
Dec 31 2022	US$1m	US$573k	-US$151m
Sep 30 2022	n/a	n/a	-US$179m
Jun 30 2022	n/a	n/a	-US$168m
Mar 31 2022	n/a	n/a	-US$154m
Dec 31 2021	US$4m	US$605k	-US$145m
Sep 30 2021	n/a	n/a	-US$142m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$137m
Dec 31 2020	US$4m	US$543k	-US$152m
Sep 30 2020	n/a	n/a	-US$164m
Jun 30 2020	n/a	n/a	-US$180m
Mar 31 2020	n/a	n/a	-US$183m
Dec 31 2019	US$921k	US$344k	-US$163m
Sep 30 2019	n/a	n/a	-US$143m
Jun 30 2019	n/a	n/a	-US$140m
Mar 31 2019	n/a	n/a	-US$246m
Dec 31 2018	US$2m	US$338k	-US$230m

Tazminat ve Piyasa: Bobby 'nin toplam tazminatı ($USD 1.45M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.40M ).

Tazminat ve Kazançlar: Bobby 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Bobby Gaspar (60 yo)

3.8yrs

Görev süresi

US$1,447,526

Tazminat

Dr. Hubert Baburaj Gaspar, M.D. Ph.D. also known as Bobby, has been Chief Executive Officer at Orchard Therapeutics plc (Formerly known as Orchard Therapeutics Limited) since March 18, 2020. He serves as a...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hubert Gaspar	CEO, Member of Scientific Advisory Board & Executive Director	3.8yrs	US$1.45m	0.16% $ 611.5k
Frank Thomas	President & COO	4yrs	US$1.21m	0.040% $ 153.8k
Nicoletta Loggia	Chief Technical Officer	2.3yrs	Veri yok	Veri yok
Fulvio Mavilio	Chief Scientific Officer	2yrs	Veri yok	Veri yok
Renee Leck	Head of Investor Relations	no data	Veri yok	Veri yok
Benjamin Navon	Director of Corporate Communications	no data	Veri yok	Veri yok
John Cerio	Chief Human Resource Officer	no data	Veri yok	Veri yok
Robin Kenselaar	Senior VP & GM of EMEA Commercial Operations	5.2yrs	Veri yok	Veri yok
Braden Parker	Chief Commercial Officer	3yrs	Veri yok	Veri yok
Leslie Meltzer	Chief Medical Officer	2.3yrs	Veri yok	Veri yok
Christopher York	Company Secretary	1.9yrs	Veri yok	Veri yok

2.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim: ORTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hubert Gaspar	CEO, Member of Scientific Advisory Board & Executive Director	7.9yrs	US$1.45m	0.16% $ 611.5k
James Arthur Geraghty	Independent Chairman	5.7yrs	US$107.72k	0.019% $ 74.1k
Marc Dunoyer	Independent Non-Executive Director	5.6yrs	US$71.72k	0.016% $ 62.1k
Charles Rowland	Independent Non-Executive Director	5.5yrs	US$90.72k	0.0054% $ 20.5k
Donald Kohn	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Alessandra Biffi	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Brian Bigger	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Simon Jones	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Adrian Thrasher	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
David Williams	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Wynn	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Harry Malech	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

5.6yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ORTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

Orchard Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Orchard Therapeutics plc, Annual General Meeting, Dec 19, 2023

Indapta Therapeutics Appoints Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations

Insufficient new directors

Insufficient new directors

Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer

Recent updates

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel)

Orchard Therapeutics Files Form 15

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

New major risk - Financial position

Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy

Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

Orchard Therapeutics plc, Annual General Meeting, Dec 19, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023

Price target decreased by 25% to US$16.00

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

New major risk - Share price stability

Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in Metachromatic Leukodystrophy and Receives Priority Review

Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 Bla in MLD At the Ssiem Annual Symposium 2023

Consensus estimates of losses per share improve by 55%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 30%

Consensus EPS estimates upgraded to US$1.61 loss

Consensus EPS estimates upgraded to US$1.81 loss

Consensus revenue estimates decrease by 18%, EPS upgraded

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

Price target decreased by 28% to US$21.60

Price target decreased by 8.7% to US$27.40

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Indapta Therapeutics Appoints Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations

Orchard Therapeutics plc Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-Of-Concept Study of OTL-201 in Mps-IIIA

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

Price target decreased to US$3.67

Insufficient new directors

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Consensus forecasts updated

Price target decreased to US$3.67

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Price target decreased to US$3.67

Price target decreased to US$4.00

Insufficient new directors

Orchard Therapeutics Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates increase by 37%

Price target decreased to US$8.64

Orchard Therapeutics plc Announces Publication in the Lancet of Long-Term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-Onset MLD

Orchard Therapeutics: Shadow Of Former Glory

Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

Consensus forecasts updated

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.20 loss in 3Q 2020)

Price target decreased to US$10.31

Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event

Consensus forecasts updated

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Consensus forecasts updated

Price target decreased to US$11.70

Orchard Therapeutics plc announced that it expects to receive $7.5 million in funding from Pharming Group N.V.

Orchard Therapeutics plc Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs

Price target decreased to US$13.00

Consensus forecasts updated

Independent Non-Executive Director Jon Ellis has left the company

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Orchard Therapeutics Announces Data Published in the New England Journal of Medicine Evaluating the Safety and Efficacy of Investigational Gene Therapy Products, Including OTL-101

Consensus revenue estimates fall to US$11.5m

Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™

Full year 2020 earnings released: US$1.53 loss per share (vs US$1.75 loss in FY 2019)

Revenue behind estimates

Orchard Therapeutics plc Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome

Orchard Therapeutics plc announced that it expects to receive $149.999996 million in funding from RA Capital Management, L.P., Avidity Partners Management LP, Casdin Capital, LLC, Farallon Capital Management, L.L.C., Citadel Enterprise Americas LLC and other investors